Management of metastatic kidney cancer in the era of personalized medicine.
about
The Past, Present, and Future in Management of Small Renal MassesInhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential.miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
P2860
Management of metastatic kidney cancer in the era of personalized medicine.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of metastatic kidney cancer in the era of personalized medicine.
@en
type
label
Management of metastatic kidney cancer in the era of personalized medicine.
@en
prefLabel
Management of metastatic kidney cancer in the era of personalized medicine.
@en
P2860
P1476
Management of metastatic kidney cancer in the era of personalized medicine.
@en
P2093
Daniel Y C Heng
Jose G Monzon
P2860
P356
10.3109/10408363.2013.869544
P577
2014-01-22T00:00:00Z